<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE To check the hypothesis that <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> supplementation may reduce <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> mellitus (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>) <z:hpo ids='HP_0003674'>onset</z:hpo> in pregnant women with a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS A 2-year, prospective, randomized, open-label, placebo-controlled study was carried out in pregnant outpatients with a parent with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were treated from the end of the first trimester with 2 g <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> plus 200 µg <z:chebi fb="9" ids="27470">folic acid</z:chebi> twice a day (n = 110) and in the placebo group (n = 110), who were only treated with 200 µg <z:chebi fb="9" ids="27470">folic acid</z:chebi> twice a day </plain></SENT>
<SENT sid="2" pm="."><plain>The main outcome measure was the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> in both groups </plain></SENT>
<SENT sid="3" pm="."><plain>Secondary outcome measures were as follows: the incidence of <z:hpo ids='HP_0001520'>fetal macrosomia</z:hpo> (&gt;4,000 g), gestational <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001622'>preterm delivery</z:hpo>, caesarean section, <z:hpo ids='HP_0011413'>shoulder dystocia</z:hpo>, <z:hpo ids='HP_0001998'>neonatal hypoglycemia</z:hpo>, and neonatal distress respiratory syndrome </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> diagnosis was performed according to the International Association of the <z:mp ids='MP_0002055'>Diabetes</z:mp> and Pregnancy Study Groups (IADPSG) recommendations </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS Incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> was significantly reduced in the <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04) </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> group, a reduction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> risk occurrence was highlighted (odds ratio 0.35) </plain></SENT>
<SENT sid="7" pm="."><plain>A statistically significant reduction of <z:hpo ids='HP_0001520'>fetal macrosomia</z:hpo> in the <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> group was also highlighted together with a significant reduction in mean fetal weight at delivery </plain></SENT>
<SENT sid="8" pm="."><plain>In the other secondary outcome measures, there were no differences between groups </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS <z:chebi fb="0" ids="17268">myo-Inositol</z:chebi> supplementation in pregnant women with a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> may reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> incidence and the delivery of <z:hpo ids='HP_0001520'>macrosomia</z:hpo> fetuses </plain></SENT>
</text></document>